The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer.
暂无分享,去创建一个
L. Duan | S. Woo | K. Kosai | B. O'Malley | S. H. Chen | D. Sewell | D. Li
[1] B. O’Malley,et al. Combination gene therapy for oral cancer in a murine model. , 1996, Cancer research.
[2] G. Forni,et al. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. , 1996, Journal of Immunotherapy with Emphasis on Tumor Immunology.
[3] X. -. Chen,et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Woo,et al. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. , 1995, Cancer research.
[5] J. Olsen,et al. Gene Therapy for Cystic Fibrosis Using E1-Deleted Adenovirus: A Phase I Trial in the Nasal Cavity. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina , 1994 .
[6] R. Grossman,et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Welsh,et al. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. , 1994, Human gene therapy.
[8] M. Welsh,et al. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. , 1993, Human gene therapy.
[9] J. Wilson,et al. Gene therapy: adenovirus vectors. , 1993, Current opinion in genetics & development.
[10] M. Perricaudet,et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium , 1992, Cell.
[11] D. Pardoll,et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.
[12] E. Gilboa,et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.
[13] B. Vogelstein,et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.
[14] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[15] G. Marshall,et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.
[16] K. Fu,et al. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. , 1984, International journal of radiation oncology, biology, physics.
[17] A. Fauci,et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. , 1983, The Journal of clinical investigation.
[18] C. Henney,et al. Cytotoxic responses: the regulatory influence of interleukin-2. , 1982, Transplantation Proceedings.
[19] C. Henney,et al. Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. , 1981, Journal of immunology.
[20] C. Henney,et al. Interleukin-2 augments natural killer cell activity , 1981, Nature.
[21] R. Gallo,et al. Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.